menu toggle

Q&A – Future challenges and predictions for CGT patient focused solutions

By AmerisourceBergen

Dale Hanna, Director, Cell and Gene Therapy (CGT) at AmerisourceBergen, partners with Dr Matthew Lakelin, Vice President, Scientific Affairs and Product Development at TrakCel, for a Q&A session. Together, they explore upcoming challenges and predictions for patient-centric solutions within the CGT field. 

They delve into sector-specific challenges, both current and anticipated in the near future, and examine the significant advantages of integrating patient hub services with cell orchestration, underscoring why developers should integrate these components into their digital supply chain.